

# Hannes Hagstrm

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6450604/hannes-hagstrom-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

89  
papers

4,423  
citations

24  
h-index

66  
g-index

102  
ext. papers

6,667  
ext. citations

6.9  
avg, IF

5.91  
L-index

#	Paper	IF	Citations
89	Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. <i>Hepatology</i> , <b>2015</b> , 61, 1547-54	11.2	1158
88	Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. <i>Hepatology</i> , <b>2017</b> , 65, 1557-1565	11.2	796
87	Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 1265-1273	13.4	423
86	Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. <i>PLoS Medicine</i> , <b>2014</b> , 11, e1001680	11.6	363
85	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , <b>2020</b> , 158, 1611-1625.e12	13.3	234
84	Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 1008-1016	18.8	113
83	Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. <i>Hepatology Communications</i> , <b>2018</b> , 2, 48-57	6	106
82	Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. <i>Gut</i> , <b>2021</b> , 70, 1375-1382	19.2	76
81	Adverse outcomes of pregnancy in women with non-alcoholic fatty liver disease. <i>Liver International</i> , <b>2016</b> , 36, 268-74	7.9	54
80	Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 1950-1956.e1	6.9	54
79	Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. <i>Annals of Internal Medicine</i> , <b>2019</b> , 171, 318-327	8	51
78	Overweight in late adolescence predicts development of severe liver disease later in life: A 39years follow-up study. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 363-8	13.4	48
77	High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men. <i>Gut</i> , <b>2018</b> , 67, 1536-1542	19.2	43
76	Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease. <i>Gastroenterology</i> , <b>2020</b> , 158, 200-214	13.3	43
75	Cardiovascular risk factors in non-alcoholic fatty liver disease. <i>Liver International</i> , <b>2019</b> , 39, 197-204	7.9	42
74	Alcohol consumption in late adolescence is associated with an increased risk of severe liver disease later in life. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 505-510	13.4	39
73	Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1148-1156.e4	6.9	38

72	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> ,	24.2	37
71	Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis. <i>Liver International</i> , <b>2019</b> , 39, 1098-1108	7.9	35
70	Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2017</b> , 52, 159-165	2.4	35
69	Retained NK Cell Phenotype and Functionality in Non-alcoholic Fatty Liver Disease. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1255	8.4	33
68	Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up. <i>Liver International</i> , <b>2016</b> , 36, 1688-1695	7.9	31
67	Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much?. <i>Current Hepatology Reports</i> , <b>2017</b> , 16, 152-157	1	30
66	Outcomes of Pregnancy in Mothers With Cirrhosis: A National Population-Based Cohort Study of 1.3 Million Pregnancies. <i>Hepatology Communications</i> , <b>2018</b> , 2, 1299-1305	6	30
65	Histologic Scores for Fat and Fibrosis Associate With Development of Type 2 Diabetes in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 1461-1468	6.9	24
64	Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries. <i>Liver International</i> , <b>2018</b> , 38, 2082-2090	7.9	24
63	SAF score and mortality in NAFLD after up to 41 years of follow-up. <i>Scandinavian Journal of Gastroenterology</i> , <b>2017</b> , 52, 87-91	2.4	24
62	Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. <i>Hepatology</i> , <b>2021</b> , 74, 2410-2423	11.2	23
61	Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1023-1029	13.4	20
60	Waist/Hip Ratio Better Predicts Development of Severe Liver Disease Within 20 Years Than Body Mass Index: A Population-based Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 1294-1301.e2	6.9	19
59	Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 1348-1354	4	19
58	Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2769-2775.e4	6.9	19
57	IGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD - a pilot study. <i>Scandinavian Journal of Gastroenterology</i> , <b>2017</b> , 52, 1427-1434	2.4	18
56	Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial. <i>JHEP Reports</i> , <b>2021</b> , 3, 100256	10.3	17
55	Alcohol, smoking and the liver disease patient. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2017</b> , 31, 537-543	2.5	16

54	Validity of administrative codes associated with cirrhosis in Sweden. <i>Scandinavian Journal of Gastroenterology</i> , <b>2020</b> , 55, 1205-1210	2.4	16
53	Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement. <i>Hepatology</i> , <b>2021</b> , 74, 474-482	11.2	16
52	Defining comprehensive models of care for NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> , 18, 717-729	24.2	16
51	Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients. <i>Gut</i> , <b>2021</b> , 70, 170-179	19.2	15
50	Quality of life as a prognostic factor for survival in hepatocellular carcinoma. <i>Liver International</i> , <b>2018</b> , 38, 885-894	7.9	14
49	Alcohol consumption in patients with primary sclerosing cholangitis. <i>World Journal of Gastroenterology</i> , <b>2012</b> , 18, 3105-11	5.6	14
48	Steatohepatitis Is Not Associated with an Increased Risk for Fibrosis Progression in Nonalcoholic Fatty Liver Disease. <i>Gastroenterology Research and Practice</i> , <b>2018</b> , 2018, 1942648	2	13
47	Pregnancy outcome in women undergoing liver biopsy during pregnancy: A nationwide population-based cohort study. <i>Hepatology</i> , <b>2018</b> , 68, 625-633	11.2	12
46	Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms. <i>PLoS ONE</i> , <b>2016</b> , 11, e0167776	3.7	12
45	Adaptation of the Charlson Comorbidity Index for Register-Based Research in Sweden. <i>Clinical Epidemiology</i> , <b>2021</b> , 13, 21-41	5.9	12
44	Transient liver elastography in normal pregnancy - a longitudinal cohort study. <i>Scandinavian Journal of Gastroenterology</i> , <b>2019</b> , 54, 761-765	2.4	11
43	Risk of Developing Pancreatic Cancer in Patients with Chronic Pancreatitis. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	11
42	Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. <i>Gut</i> , <b>2021</b> ,	19.2	11
41	The prediction of colorectal cancer using anthropometric measures: A Swedish population-based cohort study with 22 years of follow-up. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 1250-1260	5.3	8
40	A pilot study of golexanolone, a new GABA-A receptor-modulating steroid antagonist, in patients with covert hepatic encephalopathy. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 98-107	13.4	8
39	Risk Behaviors Associated with Alcohol Consumption Predict Future Severe Liver Disease. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 2014-2023	4	7
38	Body composition measurements and risk of hematological malignancies: A population-based cohort study during 20 years of follow-up. <i>PLoS ONE</i> , <b>2018</b> , 13, e0202651	3.7	6
37	Maternal obesity increases the risk and severity of NAFLD in offspring. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 1042-1048	13.4	6

36	Lifestyle Factors in Late Adolescence Associate With Later Development of Diverticular Disease Requiring Hospitalization. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1474-1480.e1	6.9	5
35	Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1592-1599.e8	6.9	5
34	A Dynamic Aspartate-to-Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver Disease. <i>Hepatology Communications</i> , <b>2021</b> , 5, 1021-1035	6	5
33	Predictive Capacity for Mortality and Severe Liver Disease of the Relative Fat Mass Algorithm. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2619-2620	6.9	5
32	Risk of Cancer in Biopsy-Proven Alcohol-Related Liver Disease: A Population-Based Cohort Study of 3410 Persons. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	5
31	Incidence of ICD-Based Diagnoses of Alcohol-Related Disorders and Diseases from Swedish Nationwide Registers and Suggestions for Coding. <i>Clinical Epidemiology</i> , <b>2020</b> , 12, 1433-1442	5.9	4
30	Etiologies and outcomes of cirrhosis in a large contemporary cohort. <i>Scandinavian Journal of Gastroenterology</i> , <b>2021</b> , 56, 727-732	2.4	4
29	Morbidity, risk of cancer and mortality in 3645 HFE mutations carriers. <i>Liver International</i> , <b>2021</b> , 41, 545-553	5.5	4
28	Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	3
27	Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1,244 individuals.. <i>Journal of Internal Medicine</i> , <b>2022</b> ,	10.8	3
26	Risk of severe COVID-19 and mortality in patients with established chronic liver disease: a nationwide matched cohort study. <i>BMC Gastroenterology</i> , <b>2021</b> , 21, 439	3	3
25	Increased Mortality Risk in Autoimmune Hepatitis: A Nationwide Population-Based Cohort Study With Histopathology. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2636-2647.e13	6.9	3
24	Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction. <i>JHEP Reports</i> , <b>2021</b> , 3, 100218	10.3	3
23	Pregnancy outcomes in women with autoimmune hepatitis - A nationwide population-based cohort study with histopathology.. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	3
22	Association between temperature, sunlight hours and alcohol consumption. <i>PLoS ONE</i> , <b>2019</b> , 14, e0223317	3.7	2
21	Body mass index in early pregnancy and future risk of severe liver disease: a population-based cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 789-796	6.1	2
20	Low Bone Mineral Density and Risk for Osteoporotic Fractures in Patients with Chronic Pancreatitis. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	2
19	Vascular Complications in Patients with Chronic Pancreatitis. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	2

18	Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease.. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> ,	5.6	2
17	Reply. <i>Hepatology Communications</i> , <b>2019</b> , 3, 848	6	1
16	Lomitapide treatment in a female with homozygous familial hypercholesterolaemia: a case report. <i>European Heart Journal - Case Reports</i> , <b>2020</b> , 4, 1-6	0.9	1
15	Reply to: "A measure of alcohol consumption in late adolescence associated with liver disease after 39 years of follow-up is insufficient to guide alcohol safe limits". <i>Journal of Hepatology</i> , <b>2018</b> , 69, 252-253	13.4	1
14	Risk of infections and their role on subsequent mortality in biopsy-proven alcohol-related liver disease.. <i>United European Gastroenterology Journal</i> , <b>2022</b> ,	5.3	1
13	Risk of hepatic and extrahepatic cancer in NAFLD: A population-based cohort study.. <i>Liver International</i> , <b>2022</b> ,	7.9	1
12	A personalized treatment program in persons with type 2 diabetes is associated with a reduction in liver steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2021</b> , 33, 1420-1426	2.2	1
11	Bariatric Surgery Versus Standard Obesity Treatment and the Risk of Severe Liver Disease: Data From the Swedish Obese Subjects Study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2675-2676.e2	6.9	1
10	Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 616212	4.9	1
9	Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease. <i>Journal of Internal Medicine</i> , <b>2021</b> ,	10.8	1
8	Serum levels of endotrophin are associated with nonalcoholic steatohepatitis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2021</b> , 56, 437-442	2.4	1
7	Is teenage heavy drinking more hazardous than we thought?. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2019</b> , 13, 603-605	4.2	0
6	Wide-field endoscopic submucosal dissection for the treatment of Barrett's esophagus neoplasia. <i>Endoscopy International Open</i> , <b>2021</b> , 9, E727-E734	3	0
5	External validation of the Toronto hepatocellular carcinoma risk index in a Swedish population. <i>JHEP Reports</i> , <b>2021</b> , 3, 100343	10.3	0
4	Cohort profile: decoding the epidemiology of liver disease in Sweden (DELIVER).. <i>Scandinavian Journal of Gastroenterology</i> , <b>2022</b> , 1-6	2.4	0
3	Reply. <i>Hepatology</i> , <b>2016</b> , 64, 310-1	11.2	
2	Reply to: "Reduced steatosis and weight as a result of specific diets or the dietitian themselves". <i>JHEP Reports</i> , <b>2021</b> , 3, 100366	10.3	
1	Hepatocellular carcinoma in Stockholm, Sweden 2003-2018: a population-based cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 1-9	2.4	

